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London, United Kingdom; Seville, Spain; and Milan, ItalyOBJECTIVES The aim of this study was to ascertain whether coronary microvascular dysfunction
(CMD) and inﬂammation are related in cardiac syndrome X (CSX).
BACKGROUND CMD can lead to CSX, deﬁned as typical angina and transient myocardial ischemia
despite normal coronary arteriograms. Inﬂammation has been suggested to play a role in the
pathogenesis of myocardial ischemia in CSX.
METHODS We assessed 21 CSX patients (age 52  10 years; 17 women) without traditional
cardiovascular risk factors and 21 matched apparently healthy control subjects. Positron emission
tomography was used to measure myocardial blood ﬂow (MBF) and coronary ﬂow reserve (CFR) in
response to intravenous adenosine, whereas high-sensitivity C-reactive protein (CRP) was measured to
assess inﬂammation. Patients were subdivided a priori into 2 groups according to CRP concentrations
at study entry (i.e., #3 or >3 mg/l).
RESULTS There were no differences in resting (1.20  0.23 ml/min/g vs. 1.14  0.20 ml/min/g;
p ¼ 0.32) or hyperemic MBF (3.28  1.02 ml/min/g vs. 3.68  0.89 ml/min/g; p ¼ 0.18) between CSX
patients and the control group, whereas CFR was mildly reduced in CSX patients compared with the
control group (2.77  0.80 vs. 3.38  0.80; p ¼ 0.02). Patients with CRP >3 mg/l had more severe
impairment of CFR (2.14  0.33 vs. 3.16  0.76; p ¼ 0.001) and more ischemic electrocardiographic
changes during adenosine administration than patients with lower CRP, and a negative correlation
between CRP levels and CFR (r ¼ 0.49, p ¼ 0.02) was found in CSX patients.
CONCLUSIONS CSX patients with elevated CRP levels had a signiﬁcantly reduced CFR compared
with the control group, which is indicative of CMD. Our study thus suggests a role for inﬂammation in
the modulation of coronary microvascular responses in patients with CSX. (J Am Coll Cardiol Img
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661n patients with chronic stable angina, myocardial
ischemia is commonly caused by ﬂow-limiting
atheromatous coronary artery stenoses. In these
patients, reductions in coronary ﬂow reserve
(CFR), deﬁned as the ratio betweenmyocardial blood
ﬂow (MBF) during maximal coronary vasodilation
(i.e., in response to adenosine) and baseline MBF,
correlate with the severity and ﬂow-limiting ability of
epicardial coronary artery stenosis (1). Recently, it hasSee page 668
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MBF = myocardial blood ﬂow
PET = positron emission
tomographybecome apparent that a large proportion of patients
with typical angina pectoris have normal coronary
angiograms (2). In these patients, a reducedCFR and
transient myocardial ischemia are likely to result from
coronary microvascular dysfunction (CMD) (3,4).
Similar mechanisms (i.e., abnormal MBF and
impaired CFR) have been documented in patients
with hypertrophic cardiomyopathy, systemic hyper-
tension, diabetes mellitus, hypercholesterolemia, and
other risk factors (3). Moreover, studies have shown
that the severity of CMD is predictive of clinical
outcome in some patient subgroups (3). Patients with
cardiac syndrome X (CSX), deﬁned as typical chest
pain, myocardial ischemia, and angiographically
normal coronary arteries, have CMD that can lead to
myocardial ischemia (4).
Inﬂammation has been shown to have a pathogenic
role in endothelial dysfunction andCMD in different
clinical settings (5–12). We have recently shown that
even in the absence of angiographic coronary artery
disease or conventional risk factors, patients with
chronic inﬂammatory conditions haveCMDthat can
lead to marked reductions in MBF and angina pec-
toris (13). Increased C-reactive protein (CRP), an
established marker of inﬂammation, is associated
with impaired endothelial function both in patients
with coronary artery disease (14,15) and CSX (5,6).
We hypothesized that inﬂammation could explain
the presence of CMD in CSX patients, even in those
without traditional cardiovascular risk factors. The
present study therefore sought to ascertain whether
elevated CRP concentrations in patients with CSX,
without conventional risk factors for coronary artery
disease, are associated with CMD, as assessed using
positron emission tomography (PET).
METHODS
Patients. We studied 21 patients (age 52  10
years; 17 women) attending St George’s HospitalChest Pain with Normal Coronary Arteries Clinic
who fulﬁlled strict criteria for CSX. All patients had
a typical history of exertional angina, a normal 12-
lead electrocardiogram (ECG) at rest, a positive
exercise ECG stress test response deﬁned as >0.1
mV horizontal or downsloping ST-segment
depression, measured 80 ms after the J point in 2
or more contiguous leads, and completely normal
coronary angiograms. Patients with angina at rest
and those with Prinzmetal’s variant angina were not
included in the study, and those with diabetes
mellitus, systemic hypertension, current or past
smoking, obesity (body mass index >30 kg/m2),
total cholesterol >5 mmol/l, or systemic inﬂam-
matory conditions were also excluded. Time elapsed
from diagnostic angiography to study entry was
<12 months in every patient. Left ventricular hy-
pertrophy was excluded by ECG and 2-dimensional
Doppler echocardiography. Patients were receiving
treatment with calcium-channel blockers,
usually diltiazem or amlodipine (n ¼ 12),
angiotensin-converting enzyme inhibitors
(n ¼ 2), and sublingual nitrates (n ¼ 20).
None of the patients were taking statins
at study entry. For the purpose of the
study, all cardiovascular medications were
withdrawn >24 h before PET assessment,
with the exception of sublingual nitrates,
which were permitted for relief of acute
chest pain at all times. One patient only,
however, used this medication, albeit >6 h
before the PET study. Twenty-one non-
smoking healthy volunteers (age 51 
10 years; 14 women) without symptoms
or a history of cardiovascular disease or
cardiovascular risk factors were also studied as a
control group.
The study protocol was approved by the local
research ethics committee, and radiation exposure
was licensed by the UK Administration of Radio-
active Substances Advisory Committee. All patients
gave written informed consent before study entry.
Routine blood tests and high-sensitivity C-reactive
protein measurement. Fasting peripheral blood
samples were obtained at study entry for the
assessment of routine biochemical variables and
inﬂammatory biomarkers. High-sensitivity CRP
(hsCRP) measurements were performed on the
COBAS Integra (Roche Diagnostics Limited,
Lewes, East Sussex, United Kingdom) using the
CRP-Latex assay in the hs application (analytical
range, 0.2 to 12 mg/l). Analytical precision of the
hsCRP latex assay was 7.6% at 1.02 mg/l, 3.3% at
1.79 mg/l, and 1.3% at 4.36 mg/l. None of the
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662patients had CRP values >12 mg/l. A CRP cutoff
point of 3 mg/l was established a priori to subdivide
patients into 2 groups (i.e., equal to or less than and
greater than 3 mg/l). The CRP cutoff point was
selected based on previous studies in CSX patients
from our group (6) showing an increased disease
“activity” (i.e., larger number of ischemic episodes
and worse ischemic responses on stress testing in
patients with hs-CRP levels >3 mg/l). Further-
more, a cutoff of 3 mg/l is widely used in the in-
ternational guidelines for the characterization of
patients into high- and low-risk groups of devel-
oping cardiovascular disease and/or events (16).
Positron emission tomography. The PET studies
were performed in a 3-dimensional imaging mode
using scanner ECAT 962 Exact HRþ (CTI/
Siemens, Knoxville, Tennessee). All emission and
transmission data were reconstructed using a ﬁltered
backprojection algorithm with a Hanning ﬁlter
(cutoff frequency, 0.5), resulting in a 3-dimensional
imaging resolution of 8.5  8.5  5.0 m3 for the
emission data at the center of the ﬁeld of view. The
scanner enables the acquisition of 15 transaxial
planes covering a 10.5-cm axial ﬁeld of view,
allowing the whole heart to be imaged.
All subjects abstained from drinking caffeine-
containing beverages for 24 h before the scan. In
patients and control subjects, regional and absolute
MBF (milliliters per minute per gram) was
measured using water labeled with oxygen-15
(H2
15O; t1/2 ¼ 2.03 min, 185 MBq). The optimal
imaging position of the left ventricle was deter-
mined by a 5-min rectilinear scan after the exposure
of an external germanium-68 ring source. For the
purpose of attenuation correction of all subsequent
scans, a 20-min transmission scan was then
acquired. An intravenous bolus of H2
15O was
injected over 20 s at an infusion rate of 10 ml/min
for measurement of baseline MBF. The venous line
was then ﬂushed with saline for another 2 min, and
the following acquisition frame times were used:
14  5, 3  10, 3  20, and 4  30 s. Ten minutes
after this ﬁrst bolus, to allow for decay of H2
15O
radioactivity, another scan was carried out during
near maximal coronary vasodilation induced with
intravenous adenosine infusion (140 mg/kg/min),
which was infused for 7 min beginning 2 min before
the second administration of H2
15O.
Our protocol was based on data by Wilson et al.
(17), who reported that the average time from the
onset of adenosine infusion to maximal vascular
response was 84  46 s (range, 23 to 125 s).
We therefore elected to start the administration of
H2
15O at 120 s, when both maximal vasodilationand a hemodynamic steady state had been achieved.
The buildup of the H2
15O is 120 s and coincides
with the upper limit of maximal response.
Cardiac rhythm was monitored continuously
throughout the procedure. Blood pressure was
measured using an automated cuff sphygmoma-
nometer, and the 12-lead ECG was recorded at
baseline, every minute during adenosine infusion,
and up to 10 min after the end of the test.
PET data analysis. The acquired sinograms were cor-
rected for attenuation and reconstructed on aMicrovax
II computer (Digital Equipment, Marlborough,
Massachusetts) using dedicated array processors
and standard reconstruction algorithms. Images
were transferred to a SUNSPARC2workstation (Sun
Microsystems, Mountain View, California) for further
analysis with dedicated software (MATLAB, the
Math-works, Natick, Massachusetts).
Myocardial images for the deﬁnition of regions of
interest were generated directly from the dynamic
H2
15O, as reported in previous studies (18). Factor
images were resliced into short-axis images in an
orientation perpendicular to the long axis of the left
ventricle. Sixteen regions of interest were drawn
within the left ventricular myocardium according to
the recommendations of the American Society of
Echocardiography (19) on 12 consecutive image
planes. Myocardial and blood time-activity curves
were then generated from the dynamic image and
ﬁtted to a single-tissue compartment tracer kinetic
model to obtain MBF values; thus, whole heart and
regional values of MBF were obtained.
Because resting MBF correlates closely with the
blood pressure-heart rate product (20), an index of
myocardial oxygen consumption, values of resting
MBF in each patient were also corrected for the
respective rate-pressure product by multiplying
basal ﬂow by the mean pressure-rate product in the
patients as a group, divided by the pressure-rate
product in the individual patient, as previously re-
ported by our group (1).
The CFR corrected for rate-pressure product was
calculated by dividing MBF during adenosine
infusion by resting myocardial ﬂow corrected for
rate-pressure product.
In addition, during adenosine infusion, we recor-
ded ischemic ECG changes, deﬁned as >0.1 mV
horizontal or downsloping ST-segment depression
in 2 or more contiguous leads, measured 80 ms after
the J point.
Statistical analysis. Results are presented as per-
centages for categorical data, as mean  1 SD for
continuous normally distributed variables, and as
median (interquartile range) for continuous
Table 1. Baseline Clinical and Hemodynamic Data in Cardiac Syndrome X Patients






(n [ 21) p Value
Age, yrs 52  12 51  8 51  10 0.97
Female 10 (76.9) 7 (87.5) 14 (66.7) 0.66
Body mass index, kg/m2* 25  3 26  2 25  3 0.63
Basal SBP, mm Hg 124  10 124  12 120  11 0.50
Basal DBP, mm Hg 70  7 71  6 69  6 0.83
Basal heart rate, beats/min 68  10 73  6 66  9 0.23
Fasting blood glucose, mmol/l 5.0  0.6 5.0  0.5 5.0  0.4 0.97
Total serum cholesterol, mmol/l 4.3  0.6 4.2  0.7 4.1  0.8 0.76
Serum triglycerides, mmol/l 1.3  0.6 1.4  0.7 1.1  0.4 0.40
CRP, mg/ly 0.5 (0.4–1.5) 4.6 (3.4–8.4) 0.5 (0.4–1.3) <0.001z
Values are mean  SD, n (%), or n (range). To convert the values for blood glucose to milligrams per
deciliter, divide by 0.05551. To convert the values for cholesterol to milligrams per deciliter mg/dl, divide by
0.02586. To convert the values for triglycerides to milligrams per deciliter, divide by 0.01129. *Body mass
index was calculated as weight in kilograms divided by the square of the height in meters. yMedian and
interquartile ranges. zBy non-parametric Kruskal-Wallis test.
CRP ¼ C-reactive protein; DBP ¼ diastolic blood pressure; SBP ¼ systolic blood pressure.
A
B
Figure 1. Myocardial Blood Flow in Control Subjects and
CSX Patients
(A) Individual baseline and submaximal myocardial blood ﬂow
values in cardiac syndrome X (CSX) patients as a group and
controls. (B) Individual baseline and submaximal myocardial blood
ﬂow values in CSX patients with C-reactive protein (CRP)
concentrations #3 mg/l and patients with CRP levels >3 mg/l.
Data are shown as mean  SD. **p < 0.001.
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663non-normally distributed data. The Kolmogorov-
Smirnov test was used to assess normal distribution.
Student 2-tailed unpaired t tests were used to
compare data values between CSX patients and the
control group. The data for MBF at rest and during
stress induced by adenosine and CFR were exam-
ined using 1-way analysis of variance and Bonfer-
roni test to localize the source of any difference.
Correlation between CRP values and CFR in pa-
tients was performed by Spearman rank test.
A 2-sided p < 0.05 was considered to indicate
statistical signiﬁcance. All statistical analyses were
performed with the Statistical Package for the Social
Sciences (version 15.0, SPSS Inc., Chicago, Illinois).
RESULTS
The demographic and clinical characteristics of
CSX patients and control group are shown in
Table 1. There were no signiﬁcant differences be-
tween groups regarding age, blood pressure levels,
and cholesterol concentrations.
Myocardial blood ﬂow. None of the patients or
normal control group showed regional abnormalities
in MBF at rest or during adenosine infusion. There
were no differences in global resting (1.20 
0.23 ml/min/g vs. 1.14  0.20 ml/min/g; p ¼ 0.32)
or hyperemic blood ﬂow (3.28  1.02 ml/min/g vs.
3.68  0.89 ml/min/g; p ¼ 0.18) between CSX
patients and control subjects (Fig. 1). A nonsignif-
icant trend toward higher resting blood ﬂow and
lower hyperemic blood ﬂow was found in the CSX
group compared with the control group. As a result,
the ratio of hyperemic/baseline blood ﬂow, which is
used for calculation of CFR, was signiﬁcantly
reduced in CSX patients compared with the control
group (2.77  0.80 vs. 3.38  0.80; p ¼ 0.02).
After correction for rate-pressure product, CFR
remained signiﬁcantly reduced in CSX patients
compared with the control group (2.71  0.68 vs.
3.30  0.81; p ¼ 0.01).
Myocardial blood ﬂow and hsCRP. Eight CSX
patients showed CRP concentrations >3 mg/l
(median 4.6; interquartile range: 3.4 to 8.4; range
3.3 to 9.0 mg/l), whereas 13 CSX patients had CRP
levels #3 mg/l (median 0.5 mg/l; interquartile
range: 0.4 to 1.5 mg/l; range 0.2 to 2.5 mg/l).
Although MBF at rest was not signiﬁcantly
different when the 2 CSX subgroups were
compared (Table 2, Fig. 1), patients with higher
CRP levels showed an impaired blood ﬂow response
to the administration of adenosine compared with
patients with lower CRP concentrations (p ¼
0.008). As a result, CFR was signiﬁcantly reducedin patients with higher CRP levels compared with
those with lower CRP concentrations (p ¼ 0.001).
Corrected CFR was reduced in patients with CRP
>3 mg/l compared with the normal control group,
Table 2. Ischemic Events and PET Measurements in Both Subgroups of
Cardiac Syndrome X Patients According to High-Sensitivity C-Reactive Protein




(n [ 8) p Value
Ischemic events 3 (21) 5 (71.4) 0.06*
MBF rest, ml/min/g 1.20  0.17 1.22  0.32 0.87
MBF peak, ml/min/g 3.72  0.98 2.56  0.62 0.008
CFR 3.16  0.76 2.14  0.33 0.001
RPP, mm Hg  beats/min 8,415  1,155 8,885  1,324 0.40
Corrected MBF rest, ml/min/g 1.23  0.15 1.17  0.22 0.49
Corrected CFR 3.01  0.64 2.21  0.40 0.005
Values are n (%) or mean  SD. *By Fisher exact test. Ischemic event was deﬁned as >0.1 mV horizontal or
downsloping ST-segment depression, measured 80 ms after the J point, in 2 or more contiguous leads
during adenosine infusion.
CFR ¼ coronary ﬂow reserve; MBF ¼ myocardial blood ﬂow; PET ¼ positron emission tomography;
RPP ¼ rate-pressure product.
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664whereas patients with CRP #3 mg/l had CFR
values comparable to those seen in the control group
(Fig. 2).
Patients with a CRP concentration >3 mg/l had
more ischemic events during adenosine stress and a
more severe reduction in corrected CFR (2.21 
0.40) compared with patients with CRP #3 mg/l
(3.01  0.64, p ¼ 0.005) (Table 2). A signiﬁcant
negative correlation between CRP levels and CFR
(r ¼ 0.49; p ¼ 0.02) was found in CSX patients
(Fig. 3).
Although none of the healthy volunteers experi-
enced chest pain or ischemic ECG changes duringFigure 2. Corrected Coronary Flow Reserve in CSX Patients
With Baseline CRP £3 mg/l, CSX Patients With CRP levels
>3 mg/l and Control Subjects
Individual (corrected) coronary ﬂow reserve values in the 2
CSX subgroups, i.e., patients with CRP values #3 mg/l and those
with >3 mg/l, and control subjects. Corrected coronary ﬂow
reserve represents the ratio of hyperemic blood ﬂow divided by
corrected baseline blood ﬂow. Error bars represent mean  SD.
Abbreviations as in Figure 1.the administration of adenosine, 6 CSX patients
had symptoms and ECG changes suggestive of
myocardial ischemia during the administration of
this agent. These patients showed a signiﬁcant
reduction in CFR and corrected CFR compared
with both the control group and CSX patients
who did not have ischemic ECG changes (2.29 
0.31 vs. 2.97  0.86; p ¼ 0.02 and 2.36  0.29 vs.
2.85  0.76; p ¼ 0.03, respectively).
D I SCUSS ION
The present study, in well-characterized CSX pa-
tients without established risk factors for cardio-
vascular disease, showed, for the ﬁrst time, a direct
relationship between hsCRP levels and abnormal
hyperemic blood ﬂow and CFR, as assessed by
PET. The study also showed that a high inﬂam-
matory status is associated with microvascular
dysfunction and may modulate the occurrence of
ischemic ST-segment changes in these patients.
These ﬁndings endorse results of previous clin-
ical studies from our group and others, that
inﬂammation can be associated with vascular
dysfunction (13,21) and myocardial ischemia (3),
even in the absence of obstructive coronary artery
disease. Reductions in CFR have been docu-
mented in asymptomatic patients with traditional
cardiovascular risk factors such as hyperlipidemia
(22–24), diabetes mellitus (9,12,25,26), and arterial
hypertension (27,28). Moreover, Rubinstein et al.
(29) showed that a higher Framingham risk score
was an independent predictor of reduced CFR
in patients without obstructive coronary disease,
thus providing further insight into the relationship
between risk factors and CFR. Our patients, how-
ever, did not have risk factors, because in the
present study, we aimed at assessing whether low-
degree inﬂammation, unrelated to conventional
risk factors, could trigger microvascular angina in
patients with CSX. We had previously shown that
patients with chronic inﬂammatory rheumatic dis-
eases could develop microvascular angina in the
absence of coronary artery disease or cardiovascular
risk factors (13).
Myocardial ischemia resulting from coronary
microvascular abnormalities has been suggested to
be a plausible pathogenic mechanism in CSX
(4,30). The causes for CMD in these patients have
not been fully elucidated, but are likely to be mul-
tiple, as discussed by Kaski (4), and more recently,
by Camici and Crea (3). Traditional cardiovascular
risk factors, insulin resistance (31), and estrogen
deﬁciency (in women) (32–34) have been reported
Figure 3. High-sensitivity CRP Levels and Corrected
Coronary Flow Reserve in CSX Patients
Correlation (linear regression) between high-sensitivity CRP and
corrected coronary ﬂow reserve in CSX patients. Corrected
coronary ﬂow reserve represents the ratio of hyperemic blood ﬂow
divided by corrected baseline blood ﬂow. Spearman’s rho ¼ 0.49,
p ¼ 0.02. The solid line represents the point estimated, and the
upper and lower dashed lines represent the 95% conﬁdence
intervals. Abbreviations as in Figure 1.
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665to be highly prevalent in subgroups of patients
with CSX and probably contribute to microcircu-
latory dysfunction in these patients. The impair-
ment of endothelium-dependent vasodilation and
the release of endogenous vasoconstrictor substances
such as endothelin-1 have also been identiﬁed as
pathogenic mechanisms in this setting (4,30). Sys-
temic inﬂammation (5,13) may also have a patho-
genic role in CSX, leading to microvascular
dysfunction, the most common cause of microvas-
cular angina in CSX patients (4).
Several studies by different authors (35–40) have
provided evidence of both reduced endothelium-
independent and endothelium-dependent coronary
vasodilation, as well as increased vasoconstrictor re-
sponses (40) in CSX patients, which could contribute
to the microvascular abnormalities found in our pa-
tients. As previously reported by Camici et al. (41), a
blunted CFR can be demonstrated in patients with
chest pain and normal coronary arteries, as assessed by
PET and using 13N-ammonia as a tracer.
Interestingly, in the present study, we found
that the subgroup of CSX patients with higher CRP
levels, compared with those with lower CRP con-
centrations, had worse CMD. This ﬁnding in-
dicates that inﬂammation can modulate coronary
microvascular responses in CSX patients, as previ-
ously suggested by studies from our group (42)
and other investigators (43), even in the absence
of conventional risk factors. Along these lines,Recio-Mayoral et al. (13), who used a similar
methodology, demonstrated that chronic systemic
inﬂammation can lead to CMD, that is, blunting of
the hyperemic response to pharmacological stress in
patients with systemic lupus erythematosus or
rheumatoid arthritis, but who do not have angio-
graphic coronary artery disease or conventional risks
factors for coronary artery disease. Findings in the
present study are also in agreement with recent
observations (29) that microcirculatory dysfunction
can be present in patients without obstructive cor-
onary artery disease, even in those with a low to
intermediate Framingham risk score. The reason for
the presence of raised CRP levels above the 3 mg/l
cutoff in some of our patients with CSX was not a
speciﬁc research goal in the present study, but will
require investigation in future studies.
Study limitations. We assessed a relatively small
number of patients, but they were extensively
investigated and matched to a normal control group,
which gives strength to our ﬁndings. We did not
systematically assess the reproducibility of CRP
measurements in this study, and therefore, cannot
categorically indicate whether the inﬂammatory
status of these individual patients remained un-
changed over time. However, we repeated the CRP
measurements (within 6 months of each other) in 13
of the 21 patients, and no signiﬁcant differences
(correlation coefﬁcient 0.79; p ¼ 0.001) were
observed between the ﬁrst and the second measure-
ments. These ﬁndings are in agreement with data in
the literature showing stable CRP concentrations
within individual patients over long periods of time,
particularly in the absence of an acute inﬂammatory
and/or infectious intercurrence (44,45). In addition,
none of the 21 patients in the study developed acute
(or chronic) inﬂammatory conditions that could have
affected their CRP levels. We did not investigate
the mechanisms responsible for the association
between inﬂammation and vascular dysfunction
observed in the study; hence, we cannot postulate the
existence of a causal relationship.
Some overlap in CFR values existed among CSX
patients with higher versus lower CRP concentra-
tions when individual patients were compared. This
might be due to the fact that although inﬂammation
has a modulatory inﬂuence on coronary vasomotor
responses, it is not the only possible cause and/or
mechanism for CMD in CSX. CSX patients have a
tendency to develop microvascular spasm and
distal epicardial coronary artery spasm or exagger-
ated epicardial coronary vasoconstriction, as recently
shown by Ong et al. (40). High endothelin con-
centrations have been reported in CSX patients
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666(4,30), and many women with CSX show estrogen
deﬁciency (32–35). These can exert marked
modulatory inﬂuences on microvascular function
and were shown to be important pathogenic
mechanisms in CSX. Hence, multiple mechanisms
in addition to inﬂammation may be operative in
CSX. The differences noted between the CSX
subgroups were small and only signiﬁcant on the
CFR rather than on the hyperemic ﬂow values. This
suggests that the magnitude of vascular dysfunction
is small.
Blunted CFR was seen in some normal subjects,
and the reason for this is speculative, but may
involve, for example, the undisclosed use of caffeine-
containing drinks before testing.
CONCLUS IONS
Findings in the present study are novel and of
importance, because they provide, for the ﬁrst
time, objective evidence for a direct relationbetween CMD and inﬂammation in CSX pa-
tients without conventional risk factors for coronary
artery disease. Future therapeutic strategies might
need to contemplate this new ﬁnding, as measures
directed toward reducing the inﬂammatory burden
in these individual patients may prove clinically
useful. An intriguing observation in the present
study is the low-degree chronic inﬂammation status
(associated with microvascular dysfunction) in a
subgroup of CSX patients, in the absence of both
conventional risk factors and chronic inﬂammatory
conditions. Further studies should attempt to
identify the source and the nature of the inﬂam-
matory process that can result in raised hsCRP
concentrations and microvascular angina in these
patients.
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